Meeting
2023 ASCO Annual Meeting
A phase II trial of nivolumab for patients with platinum-refractory recurrent or metastatic salivary gland cancer.
Authors
Yoshiaki Nagatani
Department of Medical Oncology and Hematology, Kobe University Hospital, Kobe-Shi Chuo-Ku, Japan
Yoshiaki Nagatani , Naomi Kiyota , Tomoko Yamazaki , Yukinori Asada , Masaaki Higashino , Masahiro Goto , Hironaga Satake , Ichiro Ota , Hirokazu Uemura , Katsunari Yane , Kaoru Tanaka , Takuma Onoe , Shigemichi Iwae , Shigeru Hirano , Yoshinori Imamura , Shiro Kimbara , Taku Nose , Taiji Koyama , Yohei Funakoshi , Hironobu Minami
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Other Head and Neck Cancer (Salivary, Thyroid)
Clinical Trial Registration Number
000029636
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 6092)
DOI
10.1200/JCO.2023.41.16_suppl.6092
Abstract #
6092
Poster Bd #
84
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
A multi-arm, phase 2, open-label study to assess the efficacy of RXC004 as monotherapy and in combination with nivolumab in patients with ring finger protein 43 (RNF43) or R-spondin (RSPO) aberrated, metastatic, microsatellite stable colorectal cancer following standard treatments.
First Author: Scott Kopetz
Poster
2016 ASCO Annual Meeting
Phase II trial of eribulin for recurrent or metastatic salivary gland cancers.
First Author: Keith D. Eaton
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Impact of time-of-day on nivolumab monotherapy infusion in patients with metastatic gastric cancer.
First Author: Yasunobu Ishizuka
Poster
2023 ASCO Annual Meeting
Nanoparticle albumin-bound (nab) paclitaxel in combination with nivolumab as treatment of recurrent or metastatic head and neck squamous-cell carcinoma (RM-HNSCC) that progressed on a PD-1 inhibitor: A single-arm, phase 2 trial.
First Author: Jared Cohen